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Assessment of Multiexponential Diffusion Features
as MRI Cancer Therapy Response Metrics
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The aim of this study was to empirically test the effect of chemo-
therapy-induced tissue changes in a glioma model as measured
by several diffusion indices calculated from nonmonoexponen-
tial formalisms over a wide range of b-values. We also compared
these results to the conventional two-point apparent diffusion
coefficient calculation using nominal b-values. Diffusion-
weighted imaging was performed over an extended range of
b-values (120–4000 sec/mm2) on intracerebral rat 9L gliomas
before and after a single dose of 1,3-bis(2-chloroethyl)-1-nitro-
sourea. Diffusion indices from three formalisms of diffusion-
weighted signal decay [(a) two-point analytical calculation using
either low or high b-values, (b) a stretched exponential formal-
ism, and (c) a biexponential fit] were tested for responsiveness
to therapy-induced differences between control and treated
groups. Diffusion indices sensitive to ‘‘fast diffusion’’ produced
the largest response to treatment, which resulted in significant
differences between groups. These trends were not observed
for ‘‘slow diffusion’’ indices. Although the highest rate of
response was observed from the biexponential formalism, this
was not found to be significantly different from the conventional
monoexponential apparent diffusion coefficient method. In con-
clusion, parameters from the more complicated nonmonoexpo-
nential formalisms did not provide additional sensitivity to
treatment response in this glioma model beyond that observed
from the two-point conventional monoexponential apparent dif-
fusion coefficient method. Magn Reson Med 64:1499–1509,
2010.VC 2010 Wiley-Liss, Inc.
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Diffusion-weighted magnetic resonance imaging (DWI)
shows promise as an imaging biomarker for treatment
response in glioma patients (1–9) as well as in a variety
of other clinical tumor types (10–16). Routine in almost
all preclinical and clinical scanners, diffusion maps can
be generated from a minimum of two images acquired at
low (b-value  100 sec/mm2) and high (b-value  1000
sec/mm2) diffusion weightings. Assuming monoexponen-
tial signal attenuation with b-value, the apparent diffu-
sion coefficient (ADC) can be calculated analytically.
The application of diffusion MRI for the detection of
early tumor treatment response was first reported using a
rodent glioma model using diffusion weightings at nomi-
nal b-values (1000 sec/mm2) (17). This initial report
has been verified and expanded by ensuing publications
using different tumor models and therapeutic agents
(1,18,19), supporting the use of diffusion MRI as a sensi-
tive imaging biomarker capable of detecting early cellular
changes in treated tumors which precede macroscopic
volumetric response.
The efficacy of this technique lies in its sensitivity to
the molecular motion of water, which is affected by cel-
lular, subcellular, and macromolecular elements that
impede otherwise free diffusion of water. Thus, thera-
peutic changes within the tumor at the cellular level can
be monitored by serial diffusion measurements (20–23).
Through thermal random motion, water molecules sam-
ple the surrounding microarchitecture within tissues at
length scales (few microns) much smaller than typical
MRI voxel resolution (millimeter). The theoretical basis
for diffusion analysis is that cell membranes and other
structures hinder the diffusion of molecules (20,24). The
magnitude of diffusion-driven displacement is altered by
tortuosity and hindering effects and can therefore be
used to infer their presence and density. Studies have
revealed that in biological systems water proton signal
attenuation due to diffusion weighting does not follow
monoexponential decay, and the deviation from mono-
exponential behavior is best observed at relatively high
b-values (3000 sec/mm2). A more accurate description
of signal attenuation with b-value over this wide b-value
range requires more complex biophysical models
(25–28).
An early interpretation of multiexponential diffusion
patterns was that water moves within two or more com-
partments representing pools of ‘‘fast’’ (extracellular) and
‘‘slow’’ (intracellular) diffusion components in the signal.
At low b-values the ‘‘fast’’ diffusion pool dominates sig-
nal attenuation, whereas at high b-values the ‘‘slow’’ dif-
fusion pool dominates leading to a biexponential form
for signal decay. Biexponential signal attenuation in DWI
has been studied extensively in a variety of biological
systems, and the physical mechanisms that govern non-
monoexponential decay continue to be an area of debate.
An alternative formalism for the nonmonoexponential
decay incorporates the underlying complexity in the dif-
fusion medium as a continuous distribution of diffusion
coefficients arising from a multiplicity of pools. Termed
the ‘‘stretched-exponential’’ formalism, Bennett et al. (29)
provided an analytical representation of the signal
attenuation as a function of the probability density with
a particular diffusion coefficient. Although this
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formalism can be used to infer the intravoxel diffusion
heterogeneity within a biological system, it does not
lend itself to straightforward association between bio-
physical compartments and signal decay. Although the
‘‘stretched-exponential’’ formalism has not been eval-
uated for its sensitivity to treatment response in tumors,
this method has shown promise for characterizing
tumors in brain cancer patients (30,31).
Research investigating the sensitivity of high b-value
DWI for treatment assessment has shown promising
results (5,32). Mardor et al. have demonstrated in
patients with malignant brain lesions that the ratio of the
diffusion coefficient from the ‘‘fast’’ pool and the ‘‘slow’’
pool signal fraction is highly sensitive to radiation-
induced changes in the tumor. This parameter not only
demonstrated a significant change from baseline as early
as 1 week post-treatment initiation but was capable of
predicting clinical outcome in all of the studied patients
(5). In contrast, conventional monoexponential ADC (in
their study, low and high b-values were 120 and 1200
sec/mm2, respectively) was found to be predictive of out-
come in only half of the patient population studied. Sen-
sitivity of high b-value DWI to treatment was also
observed in a colon cancer mouse model (32). These
authors used the area under the normalized nonmonoex-
ponential diffusion curve to quantify the diffusion char-
acteristics of the tissue. This diffusion index was found
to provide early prognostic information on animal
responsiveness to treatment.
In this study, three nonmonoexponential diffusion for-
malisms applied over an extended range of b-values
(120–4000 sec/mm2) were tested against the conventional
two-point ADC measurement to determine their sensitiv-
ity to therapy-induced changes of tissue using a rodent
brain tumor model. Results showed similar time
response curves for all diffusion indices following treat-
ment. Although the highest fractional change following
treatment was observed using the biexponential formal-
ism, these results were not significantly different from




9L gliosarcoma cells were obtained from the Brain Tu-
mor Research Center at the University of California in
San Francisco. The cells were grown as monolayers in
10 cm2 sterile plastic flasks in DMEM with 10% fetal bo-
vine serum, 100 IU/mL penicillin, 100 mg/mL streptomy-
cin, and 2 mmol/L L-glutamine in an incubator held at
37C and 95%/5% air/CO2 atmosphere. Before implanta-
tion, cells were harvested by trypsinization, counted,
and resuspended in serum-free medium for injection.
Tumor implantation was performed on Male Fischer
344 rats (Harlan Sprague-Dawley, Indianapolis, IN),
weighing 125–150 g, as previously described (33).
Briefly, animals were anesthetized with a ketamine/xyla-
zine mixture (87/13 mg/kg) administered intraperitoneal.
A small incision was then made over the right hemi-
sphere of the cranium. A 1 mm diameter burr hole was
drilled through the skull using a high-speed surgical
drill, and a 5 mL suspension containing 1  105 9L cells
was injected through the burr hole to a depth of 3 mm.
After injection of the cells, the burr hole was filled with
bone wax to prevent extracranial extension of the tumor,
and the surgical area was cleaned using 70% ethanol.
Vetbond (3M, St. Paul, MN) was used to close the inci-
sion until healed.
Chemotherapy
Once the tumors reached 40–80 mm3 as quantified using
T2-weighted MRI, pretreatment diffusion-weighted (DW)
images (details below) were acquired for all animals. At
the time of treatment, 1,3-bis(2-chloroethyl)-1-nitrosourea
(BCNU) (LKT Laboratories, St. Paul, MN) was freshly
prepared and formulated to a final concentration of 5
mg/mL BCNU in 10% ethanol. Subsequent to their pre-
treatment DWI scan, animals either received a single
bolus intraperitoneal injection of BCNU (9.98 mg/kg; n ¼
13) or 10% ethanol as the control vehicle (n ¼ 10). Typi-
cally, tumors increased in volume by 400% over the du-
ration of the study (2 weeks post-treatment initiation),
and euthanasia was accomplished by CO2 overdose.
MRI Scans
During MRI examinations, animals were anesthetized
with 1–2% isoflurane/air, and body temperature was
maintained by blowing warm air through the bore of the
magnet using an Air-Therm (World Precision Instru-
ments, Sarasota, FL). MR scans were performed immedi-
ately before treatment and every 3 days thereafter using a
9.4 T, 16 cm horizontal bore Varian (Palo Alto, CA)
Direct Drive system with a quadrature rat head coil (Doty
Scientific, Inc., Columbia, SC). DW images were acquired
using a spin-echo sequence, with a navigator echo and
gradient waveforms sensitive to isotropic diffusion (34),
with the following parameters: repetition time (TR)/echo
time (TE) ¼ 4000/41 msec, field of view (FOV) ¼ 30 mm,
matrix size ¼ 64  64, slice thickness ¼ 2 mm, number
of slices ¼ 8, sweep width ¼ 50 kHz, gradient pulse
width ¼ 10.5 msec, gradient pulse separation ¼ 25 msec,
and b-values (x-gradient, y-gradient, and z-gradient
amplitudes) of 120 (5.3, 4.8, and 4.2 G/cm), 1200 (16.6,
15.0, and 13.1 G/cm), 1600 (19.1, 17.3, and 15.6 G/cm),
2000 (21.3, 19.2, and 17.4 G/cm), 3000 (25.9, 23.4, and
21.3 G/cm), and 4000 sec/mm2 (29.7, 26.9, and 24.6 G/
cm) with averages of 1, 1, 1, 1, 4, and 16, respectively.
DWI scans were constrained to a total scan time of 2 h
based upon an institutionally approved animal protocol.
In addition to the time constraint, only voxels in the
tumor with a signal to noise (SNR) > 6 at high diffusion
weighting (i.e., b ¼ 4000 sec/mm2) were evaluated. The
first step in maintaining this constraint was to determine
a voxel size that provides adequate SNR and resolution
within a 2 h MR experiment. As observed in Chenevert
et al. (3), 9L rodent brain tumors treated with 13.3 mg/kg
BCNU can exhibit an ADC as high as 1.5  103 mm2/
sec. A sucrose phantom of 15% sucrose/water, with a
measured ADC of 1.4  103 mm2/sec over the b ¼ 120–
1200 sec/mm2 range, was used to determine sequence
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parameters (i.e., FOV, slice thickness, and averages) that
provide a SNR > 6 at b ¼ 4000 sec/mm2 (35).
Postprocessing of Diffusion-Weighted Images
All MRI data were transferred to a PC, interpolated to a
matrix size of 256  256, and analyzed using in-house
software developed in MATLAB (The MathWorks, Inc.,
Natick, MA). Diffusion signal decay, found to follow a
nonmonoexponential trend in healthy brain tissue and
tumor from our animal model, was analyzed using three
diffusion approaches.
Two-Point Analytical Formalism
The simplest of all three techniques investigated cap-
tures the nonmonoexponential trends observed in the
DW images from a two-point subsampling of the signal
decay curve using the following equation:
ADC12 ¼ ln S1
S2
 
b2  b1ð Þ; ½1
where S1 and S2 are the signal intensities at b-values b1
and b2, respectively, and ADC1–2 is the diffusion coeffi-
cient obtained using b1 and b2. The conventional mono-
exponential ADC was calculated using b-values of 120
and 1200 sec/mm2 (ADC120–1200), which captures the
rapid diffusion decay in the nominal-b regime while
avoiding perfusion effects observed at very low b-value
(<100 sec/mm2). Slow diffusion decay, observed in the
high-b regime, was captured by determining the ADC
using b-values of 2000 and 4000 sec/mm2 (ADC2000–4000).
The ratio of ADC2000–4000/ADC120–1200, defined as RTP,
was used as an empiric index of nonmonoexponential
behavior derived from the piece-wise two-point formal-
ism. An RTP close to one implies monoexponential
behavior, whereas a decreasing RTP implies greater dis-
parity in signal decay between low-b and high-b regimes,
thus greater multiexponential behavior.
Stretched Exponential Formalism
This formalism defines the divergence of a diffusible par-
ticle from monoexponential trends as anomalous diffu-
sion (29,36). Referred to as the stretched exponential,
this formalism portrays molecular diffusion in a locally




where S is the signal intensity at a given b-value, S0 is
the signal intensity with no diffusion weighting, DDC is
the distributed diffusion coefficient, and a is the anoma-
lous exponent bound between 0 and 1 (29,36). By
inspection of Eq. 2, it should be clear an a ¼ 1 is equiva-
lent to monoexponential diffusion signal decay. Con-
versely, an a approaching 0 indicates a high degree of
multiexponential signal decay, thus a will be used as the
nonmonoexponential index derived from the stretched
exponential formalism. This convention maintains con-
sistency with Bennett et al.’s (29) definition of a as a dif-
fusion heterogeneity index, although we remind the
reader that a numerically high a value (1) represents a
low intravoxel diffusion heterogeneity approaching
monoexponential decay, whereas a numerically low a
value represents a high degree of diffusion heterogeneity
exhibited as multiexponential decay. It is also worth em-
phasis that the term ‘‘heterogeneity’’ in this context refers
to intravoxel heterogeneity of exponential decays, as
opposed to intervoxel heterogeneity of diffusion coeffi-
cients as often is the case, particularly in tumor. Parame-
ter maps of DDC and a were calculated by linearizing
the stretched exponential equation and then fitting it to
the DW images in a pixel-wise manner over all b-values
using a linear least-squares technique.
Biexponential Model
Calculation of the biexponential diffusion components
was performed by a pixel-wise fit to all DW images of
the following equation:
SðbÞ ¼ S0 V1eðbD1Þ þ V2eðbD2Þ
 
½3
where S and S0 are signal intensities at a given b-value
and no diffusion weighting, respectively, D1 and D2 are
the fast and slow diffusion coefficients, respectively, and
V1 and V2 are the fast and slow signal fraction contribu-
tions, respectively. The fractional signal components are
related by the expression V2 ¼ 1  V1. The fit was per-
formed using a nonlinear least-squares technique.
Image Analysis
Volumes of interest (VOI) over the tumors were manually
contoured on the low b-value DWI, which exhibits T2-
weighted contrast and serves for quantification of tumor
volume. Low SNR voxels were excluded before calcula-
tion of mean parameter values within the VOI from each
diffusion formalism. To accomplish this, voxels having
SNR  6 on the b ¼ 4000 sec/mm2 DWI were identified
by software in a binary 3D mask. The mask was then
applied to all DW images guaranteeing that only those
voxels with a SNR > 6 were evaluated. Regions of necro-
sis or blood pools, typically observed as hypointense on
T2-weighted images, were manually omitted from the
VOIs. Parameter change with respect to treatment was
assessed using the percent change of the mean of each
parameter (100[Posttherapy  Pretherapy]/Pretherapy).
Histology
An additional six animals were used for obtaining histol-
ogy of the tumors for control (n ¼ 3) and treated animals
(n ¼ 3) 6 days post-treatment. 9L tumors from these ani-
mals were placed in buffered formalin overnight, dehy-
drated in 70% ethanol, and subsequently embedded in
paraffin. Tissue sections were prepared for histological
processing by routine techniques. Briefly, paraffin sec-
tions (5 mm thick) were cut on a microtome and heated
for 20 min at 65C. Slides were deparaffinized in xylene
with three changes for 5 min each and then rehydrated
through an alcohol gradient for 2 min each (100% alco-
hol, 95% alcohol, and 70% alcohol). Sections were first
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stained using a Gill’s 2 hematoxylin solution and then
subsequently stained with eosin.
Statistics
A paired Student’s t-test was used to assess significance
between the percent change in each parameter post-treat-
ment initiation from pretreatment values and between
the percent change in similar parameters for each formal-
ism at individual time points in the treated group. Group
comparisons were assessed for each parameter at indi-
vidual time points using an independent sample Stu-
dent’s t-test. Treatment efficacy on overall survival was
assessed by log-rank test and displayed using a Kaplan-
Meier survival curves. All statistical computations were
performed with a statistical software package (SPSS Soft-
ware Products, Chicago, IL). Statistical significance was
assessed at P < 0.05.
RESULTS
Representative DW images, acquired at b-values of 120,
1200, 3000, and 4000 sec/mm2, are demonstrated in
Fig. 1. Using low b-value images, delineation of tumor
extent allowed for tumor volumes to be measured over
time. Although the tumor volume in treated animals did
appear to have a slower rate of growth than controls, this
did not result in statistical differences in tumor volume
between groups at individual time points (Fig. 2a).
Nevertheless, as presented in Fig. 2b, the median sur-
vival of treated animals (9 days with a 95% confidence
interval of 8.2–9.8 days) was found to be significantly
longer than control animals (5 days with a 95% confi-
dence interval of 3.8–6.2 days; P ¼ 0.001). Increased lon-
gevity in treated animals was consequent to tumor cell
death, which was verified by histology. Histological sec-
tions of representative control and treated animals at day
6 post-treatment initiation are presented in Fig. 3. Fol-
lowing BCNU treatment, fewer nuclei were observed in
the treated tumor than control, suggesting massive cell
kill in the tumor volume of treated animals. An increase
in pleomorphism and giant cells was also evident in the
treated tumors. Tumor growth rate kinetics and histology
were consistent with previous findings using the 9L glio-
sarcoma rat brain tumor model (5).
Presented in Table 1 is a summary of the parametric
indices generated from the three formalisms for control
and treated tumor groups acquired at baseline. Signifi-
cant differences in indices with similar diffusion proper-
ties were observed between all formalisms. In contrast,
group comparisons did not result in statistical differen-
ces for any given parameter (Table 1: parameter values
FIG. 1. Representative diffusion-weighted images of a rat brain harboring a 9L gliosarcoma acquired at b-values of (a) 120, (b) 1200,
(c) 2000, and (d) 4000 sec/mm2. Images were independently scaled for better visualization at higher b-values.
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for control and treated animals are summarized in the
top and bottom rows, respectively). To verify the accu-
racy of our biexponential fit to the data, pretreatment
values were calculated in healthy rat striatum. Biexpo-
nential results of D1 and V1 (0.88  103 mm2/sec and
0.79) were found to be comparable with previous values
FIG. 2. a: Plot over time of the mean tumor volume. Data presented as mean 6 SEM. Significant difference in mean tumor volume
between groups was assessed using an unpaired Student’s t-test. P values are provided at individual time points. b: Kaplan-Meier sur-
vival plot for overall survival is presented for control and treated animals. Controls are shown as solid line with diamond markers and
treated are shown as dashed lines with square markers. Significant differences in overall survival were observed between groups as
assessed using a log-rank test (P ¼ 0.001).
FIG. 3. Hematoxylin–eosin-stained sections of intracerebral 9L tumors for representative (a) control and (b) BCNU-treated animals on
day 6 post-treatment.
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in brain tissue (28). In contrast, D2 (0.42  103 mm2/
sec) was 2.5 that of Niendorf et al.’s measurement of
0.165  103 mm2/sec (28).
As shown in Fig. 4, maps of parameters more sensitive
to ‘‘fast diffusion’’ properties pretreatment (left column)
and 6 days following BCNU treatment (right column)
Table 1




ADC120–200 [102 mm2/sec]. DDC [103 mm2/sec] D1 [103 mm2/sec]
1.02 (0.02) 0.97 (0.02) 1.39 (0.05)
0.99 (0.03) 0.95 (0.02) 1.38 (0.05)
ADC2000–1000 [103 mm2/sec] D2 [103 mm2/sec]
0.71 (0.02) 0.68 (0.03)
0.69 (0.01) 0.62 (0.02)
RTP a V2
0.71 (0.02) 0.83 (0.01) 0.39 (0.01)a
0.71 (0.02) 0.87 (0.01) 0.35 (0.01)a
ADC120–200/RTP DDC/a D1N2
1.46 (0.07) 1.10 (0.04) 3.99 (0.18)
1.48 (0.05) 1.09 (0.03) 3.74 (0.19)
Pretreatment data are presented for controls (n ¼ 10; top) and treated (n ¼ 13; bottom) animals as means (SEM).
aThe slow fractional signal intensity is provided because of similar trends to RTP and a post-treatment initiation.
FIG. 4. Representative maps and line plots of percent change in parameters sensitive to ‘‘fast diffusion’’ generated using (a, d, g) two-
point, (b, e, h) stretched-exponential, and (c, f, i) biexponential formalisms are provided. Diffusion maps, overlaid on T2-weighted
images of a rat brain, were acquired at days 0 (a, b, c) and 6 (d, e, f) post-treatment initiation. Line plots (g, h, i) consist of mean values
and standard errors from control and treated groups over the entire experiment. Data are presented as the mean 6 the standard error
of the mean. The symbols y and * designate significant differences from baseline and between groups, respectively. Statistical signifi-
cance was assessed at P < 0.05. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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were generated over the tumor volume and superim-
posed on T2-weighted images. Top-row images (Fig.
4a,d) represent ADC120–1200, middle-row images (Fig.
4b,e) are DDC, and bottom-row images (Fig. 4c,f) are D1.
In addition, the full time course of ADC120–1200, DDC,
and D1 expressed as percent change from pretreatment
values are illustrated in Fig. 4g–i, respectively. D1 was
found to be significantly larger than ADC120–1200 and
DDC at baseline (Table 1) and at day 6 post-treatment
initiation as well as having, in absolute terms, a larger
dynamic range (1.5–3.0  103 mm2/sec) within the tu-
mor volume allowing easier visualization of tumor fea-
tures (Fig. 4c,f). As for the responsiveness of these indi-
ces to treatment, the percent change from baseline
peaked at day 6 post-treatment initiation, followed by a
descent toward baseline at day 9 (Fig. 4g–i). Near identi-
cal trends were observed for ADC120–1200 and DDC with
significant group and baseline value differences observed
on days 3 and 6. Similar results were observed for D1
except for the negligible group differences at day 3 post-
treatment initiation, which is attributed to the slower
rate of ascent from baseline (Fig. 4i). Although change in
D1 was found to be most responsive to treatment with a
25% increase at day 6 from baseline, it was not found
to be significantly larger at this time point or any other
time point from what was observed for change in
ADC120–1200 and DDC (P ¼ 0.204 and P ¼ 0.711, respec-
tively, for day 6).
Analogous parametric maps and line plots to Fig. 4 are
illustrated in Fig. 5 for quantities sensitive to the ‘‘slow
diffusion’’ component of the decay curve, namely
ADC2000–4000 (Fig. 5a,c,e) and D2 (Fig. 5b,d,f). In general,
ADC2000–4000 and D2 showed little change in day 6 val-
ues from baseline (Fig. 5a–d). Percent change in the
mean values over time corroborates observations found
in the maps from the representative animal (Fig. 5a–d)
with ADC2000–4000 and D2 peaking at less than 10% of
baseline. Group differences were only observed at day 3
for D2, partly attributed to a drop in control D2. Interest-
ingly, both ADC2000–4000 and D2 resulted in 7%
decrease from baseline on day 9 post-treatment initiation
(Fig. 5h,i), which correlated with the descent back to
pretreatment values observed in diffusion coefficients
sensitive to ‘‘fast diffusion’’ (Fig. 4).
As discussed previously, a comparison of the absolute
numerical value of nonmonoexponential metrics is not
meaningful because of differences in how these parame-
ters are defined. Qualitatively, RTP was most sensitive to
treatment exhibiting the largest percent drop from base-
line values (Fig. 6). The remaining parameters showed
similar qualitative trends from baseline to day 6 post-
treatment initiation. A significant drop from pretreat-
ment values was observed at day 6 for RTP (11%), a
(7%), and V2 (6%). RTP and a continued to have sig-
nificantly lower values to baseline at day 9, which was
not established by V2 because of scatter in the data.
Group differences were only found at day 6 for RTP and
a. The ratio of D2 and D1, as obtained from the biexpo-
nential formalism, provided analogous results to RTP
(data not shown). Although the mean value of D2/D1
decreased by more than 15%, these results were not
found to be statistically different from the controls.
DISCUSSION AND CONCLUSIONS
DW MRI has shown potential as a surrogate biomarker
for treatment response in cancer patients (37–40). Acqui-
sition of diffusion maps is typically performed at
FIG. 5. Representative maps of the ‘‘slow diffusion’’ coefficients and line plots of percentage change in parameters generated using (a, c,
e) two-point and (b, d, f) biexponential formalisms are provided. Diffusion maps, overlaid on T2-weighted images of a rat brain, were
acquired at days 0 (a, b) and 6 (c, d) post-treatment initiation. Line plots (e, f) consist of mean values and standard errors from control and
treated groups over the entire experiment. Data are presented as the mean 6 the standard error of the mean. The symbols y and * desig-
nate significant differences from baseline and between groups, respectively. Statistical significance was assessed at P < 0.05. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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relatively moderate diffusion weighting, i.e., b-values
that typically span the 0–1000 sec/mm2 range. It is
speculated that water diffusion measurements at higher
b-values may provide increased sensitivity to relevant
drug-induced changes in tumor composition by virtue of
possible therapeutic alteration of cellular constituents
responsible for the ‘‘slow diffusion’’ components of sig-
nal decay observed at relatively high b-values. This
study sought to determine the sensitivity of diffusion
parameters derived from various mathematical formal-
isms of nonmonoexponential water diffusion to treat-
ment-induced tissue alteration following treatment of the
9L glioma model.
Previous work by our group using the 9L brain tumor
model has shown that ADC calculated using moderate
b-values can increase by up to 60% within a week fol-
lowing a single dose (13.3 mg/kg) of BCNU (3). As meas-
ured in this study, parameters sensitive to ‘‘fast diffu-
sion’’ showed similar trends following a single bolus
(9.98 mg/kg) of BCNU, all peaking by day 6 post-treat-
ment initiation. The maximum percent change in param-
eter value from baseline was observed in D1. This is
expected because D1 is a more specific measurement of
‘‘fast diffusion’’ than DDC and ADC120–1200, which are
not completely devoid of the ‘‘slow diffusion’’ properties
in the signal decay curve. A positive therapeutic effect
was confirmed by an increased overall survival (Fig. 2)
as well as direct evidence from histological tumor sec-
tions comparing treated versus untreated tumors (Fig. 3).
Another characteristic trend of ADC following treatment,
which has been observed here and by others, is the tem-
porally evolving descent to baseline values. This has
been found to correlate with tumor cell repopulation,
which has been reported in the literature (28). In con-
trast, those indices specifically sensitive to ‘‘slow diffu-
sion’’ exhibited a negligible change post-treatment initia-
tion until day 9 where a drop had occurred in both
parameter values when compared with baseline. The
lack of response following treatment and the sudden
drop in ADC2000–4000 and D2 during cell repopulation,
which is reflected in the diffusion coefficients sensitive
to ‘‘fast diffusion’’ descent to baseline, is quite perplex-
ing, suggesting independent mechanisms affecting the
‘‘fast’’ and ‘‘slow’’ diffusion properties of the tissue.
Additional mechanisms, such as macrophage infiltration
and clearance of macromolecules, may also contribute to
our observations. Despite subtle variations in the trends
of the parameters with either ‘‘fast’’ or ‘‘slow’’ diffusion
FIG. 6. Representative nonmonoexponential metric maps and line plots of percentage change in parameters generated using (a, d, g)
two-point, (b, e, h) stretched-exponential, and (c, f, i) biexponential formalisms are provided. Metric maps, overlaid on T2-weighted
images of a rat brain, were acquired at days 0 (a, b, c) and 6 (d, e, f) post-treatment initiation. Line plots (g, h, i) consist of mean values
and standard errors from control and treated groups over the entire experiment. Data are presented as the mean 6 the standard error
of the mean. The symbols y and * designate significant differences from baseline and between groups, respectively. Statistical signifi-
cance was assessed at P < 0.05. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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properties, there was no significant difference in the per-
cent change from baseline between diffusion parameters
with like properties.
As opposed to the diffusion coefficients, the nonmo-
noexponential metrics, RTP, a, and V2, are defined differ-
ently and thus cannot have the same interpretation, even
though they have similar trends. Consequent to the neg-
ligible change in ADC2000–4000, RTP is driven almost
exclusively by ADC120–1200 for most of the study. Not
until day 9, did we see a divergence from this depend-
ence, which is partly attributed to the mirrored descent
observed in ADC2000–4000 to ADC120–1200 resulting in a
negligible change in RTP from day 6 to day 9 post-treat-
ment initiation. Analogous but not significant results
were observed for D2/D1. Large variability in the mea-
surement of D1 and D2 (Figs. 4 and 5) from the nonlinear
fit most likely contributed to the nonstatistical differen-
ces in D2/D1 between groups. In contrast, the slow diffu-
sion signal fraction, V2, defines the proportion of water
signal in the slow compartment independent of water
diffusivity. The drop in V2 suggests shrinkage of the
slow compartment volume fraction, conversely an expan-
sion of the fast compartment volume fraction, following
treatment initiation. The anomalous exponent a repre-
sents the deviation of signal attenuation from monoexpo-
nential behavior (a ¼ 1). This perturbation is assumed to
be attributed to increased heterogeneity within the tis-
sue. The decrease in a seen in Fig. 6h suggests an
increase in tumor intravoxel heterogeneity that maxi-
mizes at day 6 and continues to day 9. Following treat-
ment of the tumor with BCNU, a loss in tumor cellularity
(Fig. 3) further deviated the attenuation curve away from
monoexponential behavior than what was observed from
control and baseline values (Table 1). Because of similar
trends in the nonmonoexponential metrics and the lack
of response to treatment of the ‘‘slow diffusion’’ indices,
one may speculate that the ‘‘fast diffusion’’ properties
within the tumor dominate what we observe for RTP, a,
and V2 following treatment. Various theories have been
proposed to provide a physical account of the deviation
in diffusion-sensitive signal attenuation from monoexpo-
nential behavior in biological tissue (20,21,41). Use of
these theories to determine the exact physical properties
that govern nonmonoexponential water diffusion war-
rants further investigation but is beyond the scope of
this study.
Irrespective of the mechanisms driving nonmonoexpo-
nential behavior in diffusion-sensitive signal attenuation,
high b-value DWI provides additional advantages over
conventional monoexponential ADC measurements that
may provide a more sensitive biomarker for tumor treat-
ment response and characterization. The conventional
approach for measuring ADC, b-values around 1000 sec/
mm2, is hindered by the presence of highly diffuse tis-
sue, such as cysts and necrotic areas, which may reside
within or around the tumor volume adding increasing
difficulty in localizing viable tumor. At higher b-values,
these rapidly diffusing regions within tumors are essen-
tially filtered out leaving only densely packed tumor that
has lower ADC values. Recent research investigating the
sensitivity of high b-value DWI for treatment assessment
has shown promising results. Mardor et al. have demon-
strated in patients with malignant brain lesions that the
ratio of D1 and V2 [defined as R in Eq. 1 of Ref. 5] is
highly sensitive to radiation-induced changes in the tu-
mor. This parameter not only demonstrated a significant
change from baseline as early as 1 week post-treatment
initiation but was capable of predicting clinical outcome
in all of the studied patients. In contrast, conventional
monoexponential ADC (comparable to ADC120–1200 in
this study) was only capable of predicting response in
about half of their patient population. It is not clear
whether R, as presented by Mardor et al., is driven by D1
or V2, or if D1 or V2 alone would provide ample sensitiv-
ity to predict tumor response to treatment as this analy-
sis was not provided in their study. We further evaluated
the approach proposed by Mardor et al. (5) (D1/V2) using
our data. The percentage change in D1/V2 from baseline
was 42% in the treated group at day 6 post-treatment,
which was significantly different from controls [2%
(P ¼ 0.002)]. Although, D1/V2 demonstrated a percentage
change 1.6 greater than that generated by D1, this
increase was not statistically different (P ¼ 0.15). The
probable cause for the lack of significance was the addi-
tional scatter in the data as a result of the nonlinear fit.
Unlike DWI at moderate b-values, acquisition of diffu-
sion-sensitized signal at b-values of >2000 sec/mm2 is
not trivial. This is attributed to the exponential loss of
signal due to increased attenuation at high b-values. As
signal approaches the noise floor, artificial nonmonoex-
ponential trends in the signal profile are observed,
adversely affecting the slow diffusion measurements. To
accommodate these losses, images must be acquired with
sufficient SNR resulting in longer scan times, which may
not result in patient compliance. Additional computa-
tional time is also required when fitting the biexponen-
tial formalism to the DWI data. In this study, 30 min
per dataset was required for the voxel-wise nonlinear fit.
The stretched-exponential formalism does not suffer
from this deficiency because it can be linearized and
solved using an algebraic solution of the linear least
squares. Numerically fitting two parameters for the
stretched exponential model can also be more stable rela-
tive to fitting three parameters required by the biexpo-
nential model.
There are several limitations to our experimental
approach that must be discussed. Scan time was limited
to no more than 2 h. This in turn limited the signal aver-
aging, i.e., SNR, and range and number of b-values used
per scanning session. As discussed, large slice thick-
nesses and small matrix sizes were used to maintain our
self-imposed constraint of SNR > 6. This likely resulted
in unavoidable partial volume averaging in the tumor,
which would be less with thinner slices. Another area of
concern was the lack of sufficiently high b-values, which
are most sensitive to ‘‘slow diffusion’’ rates. This could
have possibly led to an overestimation of the D2 in the
biexponential fit. Using the mean D1 and D2 determined
at day 6 post-treatment initiation, we found in treated tu-
mor tissue (1.7  103 mm2/sec and 0.6  103 mm2/
sec), less than 4% (exp(2000*0.0017) 3.3%) of the
fast diffusion signal was still present at a b-value of 2000
sec/mm2, whereas 29.9% of the slow diffusion compo-
nent signal was still available. Finally, the biexponential
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diffusion coefficients, D1 and D2, acquired here for
healthy striatum varied by only a factor of 2, contrary to
the factor of 5–10 typically observed in the literature.
Based on the observations of biexponential diffusion in
rodent models, D1 as measured in this study is in ac-
cordance with literature results (0.88 here, compared to
0.82 and 0.77  103 mm2/sec in the literature), whereas
D2 appears to be overestimated by a factor of 2 (0.43
here, compared to 0.17 and 0.18  103 mm2/sec in the
literature) (28,41). The discrepancy in D2 is most prob-
ably due to the lack of sufficiently high b-values used in
this study. Finally, the filtering of low SNR voxels from
our whole-tumor analysis may have inadvertently
removed necrotic regions in the tumor. Signal intensity
within regions of high diffusivity or short T2 due to
blood products is prone to have low signal at high
b-value. As discussed earlier, the contribution of noise
in our data was reduced by filtering voxels whose SNR
< 6 on the highest weighted DWI (4000 sec/mm2). This
maintained voxels having high SNR at high b-values but
removed regions of high diffusivity or low SNR (i.e., ne-
crosis, cystic, and blood products) from the whole-tumor
analysis. To avoid excessive loss of tumor volume while
maintaining SNR  6, image matrix size and slice thick-
ness were set to maintain adequate SNR at a cost of reso-
lution. The volume fraction of tumor analyzed at days 6
and 9 post-treatment initiation in treated animals was
93.5% 6 11.3% and 94.5% 6 9.9% (means 6 SD),
respectively. Based on these values, filtering tumor
regions that contribute to low SNR in DWI at high b-
value did not result in excessive loss of tumor volume
for our analysis in this study.
We have demonstrated the sensitivity of various non-
monoexponential diffusion formalisms for monitoring
early response to chemotherapeutic treatment for brain
tumors in an animal model. The extent of the response
varied, with the fast diffusion component of the biexpo-
nential formalism exhibiting the largest percent change
from baseline than other diffusion coefficient; slightly
more than was observed in the conventional monoexpo-
nential ADC and DDC measurements. However, for this
9L glioma model treated with a single dose of BCNU, the
more complicated formalisms provided no additional
sensitivity to treatment response over what was observed
using conventional monoexponential ADC measured
over the standard modest b-value range.
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